As you rush to buy something for your mom, con artists will be trying to make a dent in your wallet. Here are some common types of fraud to look out for not only this Mother's Day.

The post Scams to watch out for not just this Mother’s Day appeared first on WeLiveSecurity

Coda Payments and Riot Games have announced that players...

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Watching Anderson Cooper CNN is like being on mushrooms Why state governments are best for reopening decisions Disbanding the task force, it’s time Moonface Ben Shapiro’s clear description of coronavirus situation If you would like my channel to have a wider audience and higher production […]

The post Episode 957 Scott Adams: Let Me Tell You About the Psychedelic Mushroom I Accidentally Ingested Called CNN appeared first on Scott Adams' Blog.

The elements of Goodrich Petroleum that make it a Buy are presented in a ROTH Capital Partners report.

A survey of over 600 private boats docked in marinas throughout the Mediterranean showed that 71% are carrying non-indigenous species. In certain cases, non-indigenous species can become ‘invasive’ and have enormous and long-lasting impacts on ecosystems. The findings suggest that a common monitoring strategy may be necessary to prevent further disruptions to natural ecosystems.

An early-warning system developed by researchers could help forest managers in Europe predict which trees are at greatest risk of bark- beetle infestation. The study looked at the probability of bark-beetle outbreaks on two important conifer-tree species in Slovenia: the Norway spruce (Picea abies) and silver fir (Abies alba). It found that high temperatures, and extreme weather linked to climate change — including droughts and ice storms — weakened trees, making them more vulnerable to attack by bark beetles.

A cache of exquisitely preserved bones, found in a coal mine in the state of Gujarat, India, appear to be the most primitive primate bones yet discovered, according to an analysis led by researchers from The Johns Hopkins University and Des Moines University. Their assessment of the bones, belonging to ancient, rat-sized, tree-dwelling primates, bolsters the controversial idea that primates native to what is now India played an important role in the very early evolution of primates, mammals that include humans, apes and monkeys.

read more

Long ago, one great ocean flowed between North and South America. When the narrow Isthmus of Panama joined the continents about 3 million years ago, it also separated the Atlantic from the Pacific Ocean. If this took place millions of years earlier, as recently asserted by some, the implications for both land and sea life would be revolutionary. Aaron O'Dea, staff scientist at the Smithsonian Tropical Research Institute (STRI), and colleagues writing in Science Advances firmly set the date at 2.8 million years ago.

read more

An international team of scientists has described a rare fossil site that is believed to be among the earliest evidence of different fish species using a common nursery -- much like ones utilized by some fish today.

read more

Soccer is an increasingly popular sport in the United States, both professionally and recreationally, with over 3 million registered soccer players under 19 years of age playing in leagues every year. A new study conducted by the Center for Injury Research and Policy of the Research Institute at Nationwide Children's Hospital found that with the increase in the number of players there has been a rise in the number and rate of injuries.

read more

An extensive field investigation discovered that 38% of soils in southwest England show signs of enhanced surface water runoff due to soil degradation. The study also revealed which types of fields and soils are linked to the most or least degradation.

Producing and consuming food has a significant environmental impact. In the search for a sustainable diet, researchers in Sweden explored a method of food production that does not exceed the level of globally available arable land per capita, and involves raising livestock on pasture or by-products not suitable for humans (the ‘ecological leftovers’ principle). The researchers developed three diets based on this method and evaluated their environmental impact compared with current diets.

The costs and benefits of sustainable land management have been collated in a new review. Data from a global archive was analysed for the costs of sustainable practices and technologies and for land users’ perceptions of cost–benefit ratios. Most respondents had a positive view of the short-term cost-benefit ratio, and a strongly positive view of the long term. Low upfront costs, long-term planning and security of land tenure were identified as important factors to facilitate these practices.

Heatwaves in Europe are likely to become more frequent and devastating, according to recent research. Climate change will lead to extended periods of high day and night-time temperatures, coupled with high humidity, and will particularly affect the Mediterranean coast and southern European river basins, where there are many densely populated urban areas.

Dire messages about the impact of global warming may increase scepticism because they contradict a commonly held belief that the world is a just and orderly place. This is the conclusion of new psychological research which investigated the reaction of individuals to messages about global warming.

New research on climate-driven reductions in Arctic sea ice has predicted that, by 2040 to 2059, new shipping routes will become passable across the Arctic, linking the Atlantic and Pacific oceans. An increase in traffic has implications for the ecosystems of this fragile area.

Ship recycling at the end of a ship’s useful life aims to make the shipping industry more environmentally sustainable and is a major source of employment in developing countries. However, there are associated health, safety and environmental concerns. This study argues these concerns are due to inappropriate design and explains how ‘design for recycling’ can reduce the costs and risks of ship recycling.

In this environment, the delivery of platform-enabled solutions at speed across the entire technology stack becomes even more important, it said. From cloud to networking, data centre to security and more, breadth and depth of capability are essential to recover and restore operations and position organisations strongly for the coming years.

Traditional services also have some very strong propositions, like digital workplace, engineering services. Some of the demand for that is intact and it is only getting accelerated.

Scheduled cleanup

The stratospheric rise in phishing and identity attacks since the beginning of the Coronavirus pandemic is give sleepless nights to CISOs across the world making them the Digital Security Warriors

The center of the Milky Way galaxy is currently a quiet place where a supermassive black hole slumbers, only occasionally slurping small sips of hydrogen gas. But it wasn't always this way. A new study shows that 6 million years ago, when the first human ancestors known as hominins walked the Earth, our galaxy's core blazed forth furiously. The evidence for this active phase came from a search for the galaxy's missing mass.

read more

New research on climate-driven reductions in Arctic sea ice has predicted that, by 2040 to 2059, new shipping routes will become passable across the Arctic, linking the Atlantic and Pacific oceans. An increase in traffic has implications for the ecosystems of this fragile area.

Travelling by coach or train has a lower impact on the climate than travelling by air or car, but using a small diesel car to carry several passengers can have similarly low impacts per person, new research suggests. Air travel is the worst form of transport, in terms of global warming impact, the researchers found, but the average percentage occupancy of a mode of transport significantly affects the impact per passenger.

Although national and European policy supports the importance of outdoor recreation, there are few binding commitments for action, according to new research. In particular, monitoring of recreation in forests is rarely mentioned in national policy and the study suggests comparable European data could inform firmer decision-making.

Informing consumers about their energy use and giving advice on how it can be improved can result in lower public energy consumption, new research suggests. However, if such information campaigns are based solely on monetary savings they are not effective, the study concludes.

Regardless of how well-designed environmental legislation is, for it to be effective it must be properly enforced. This study explored the enforcement practices of several environmental agencies, recommending that strategies are chosen based on regulatory context and environmental risk.

Significant savings on mileage and vehicle costs can be achieved by using computer optimisation to plan waste collection routes, new research suggests. When applied to a case study of cooking oil recycling in Portugal, it was found that the technique could lead to a reduction of 13% in annual distance travelled and a fleet hiring cost reduction of 11%.

Small, artificial wetlands can reduce river pollution by trapping soil and nutrients swept off agricultural land by rainfall, a recent study finds. The researchers recommend that they are used as a back-up option to soil management measures also designed to reduce runoff into rivers.

Unusually warm or cool Pacific sea surface temperatures, known as El Niño and La Niña, can be used to reliably predict anomalies in flood risk for river basins that cover 44% of the Earth’s land surface, a new study has shown. The researchers also quantified overall flood damage by combining information on flood risk with estimates of damage to economies and numbers of people at risk. This could help improve flood disaster planning, they say.

A new study has looked at the potential of green infrastructure to compensate for the effects of soil sealing generated by urban development. It investigates how green roofs and permeable paving could contribute to flood mitigation in southern Italy. Using a hydraulic model technique, the researchers found that, in this particular urban case, green roofs were more effective than permeable paving. Policies to promote the adoption of sustainable urban drainage systems (SUDS) by the private sector could thus prove more effective under certain circumstances, and policymakers should look at ways to promote SUDS where suitable.

Xiaomi India Managing Director said that the company does not collect any user data that the user has not explicitly given permission or consent to. He added that in the browser's incognito mode, all user data is completely encrypted and anonymised. He also pointed out that all Mi Browser and Mi Cloud data of Indian users is stored locally in AWS servers in India.

The stratospheric rise in phishing and identity attacks since the beginning of the Coronavirus pandemic is give sleepless nights to CISOs across the world making them the Digital Security Warriors

Chinese smartphone maker Oppo expects the Covid-19 supply chain disruption to end in a week or two. It is also planning to open a 5G lab in Hyderabad.